<DOC>
	<DOCNO>NCT00338143</DOCNO>
	<brief_summary>This Phase IIIb , open label , uncontrolled , multicenter study design evaluate safety tolerability 12 week subcutaneously administer efalizumab subject moderate severe plaque psoriasis candidate systemic therapy may also receive topical therapy , PUVA , UVB phototherapy efalizumab treatment period .</brief_summary>
	<brief_title>A Study Evaluate Efalizumab Adults With Plaque Psoriasis , Including Those Who Are Receiving Concomitant Antipsoriatic Therapies</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed informed consent Plaque psoriasis cover &gt; =10 % total BSA Plaque psoriasis diagnose least 6 month In opinion investigator , candidate systemic therapy psoriasis 1875 year old Body weight &lt; =125 kg For woman childbearing potential , use acceptable method contraception prevent pregnancy agreement continue practice acceptable method contraception duration participation study 3 month last dose efalizumab Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis Pregnancy lactation Clinically significant psoriasis flare screen time enrollment History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity hepatitis B C virus Seropositivity human immunodeficiency virus ( HIV ) History active tuberculosis ( TB ) currently undergo treatment TB Presence history malignancy within past 5 year , include lymphoproliferative disorder Previous treatment efalizumab ( antiCD11a ) Diagnosis hepatic cirrhosis , regardless cause severity Hospital admission cardiovascular pulmonary disease within last year History severe allergic anaphylactic reaction monoclonal antibody fusion protein , contain Ig Fc region ( e.g. , etanercept , alefacept ) History treatment lymphocytedepleting monoclonal antibody immunoadhesion molecule ( e.g. , antiCD4 , CTLA4Ig , alefacept ) White blood cell ( WBC ) count &lt; 4000/uL &gt; 14,000/uL Hepatic enzyme &gt; = 3 time upper limit normal Creatinine &gt; = 2 time upper limit normal Use experimental drug treatment within 30 day five halflives , whichever longer , prior first dose efalizumab Use live virus live bacteria vaccine 14 day prior first dose efalizumab Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug would significantly interfere subject 's ability comply provision protocol Restrictions and/or direction apply follow treatment specified time period prior efalizumab treatment period : Systemic therapy psoriasis ( biologic nonbiologic ) ; Systemic immunosuppressive drug condition psoriasis ; Live virus bacteria vaccine ( vaccine may include , limited , measles , mumps , rubella , polio , BCG , yellow fever , TY21a typhoid ) ; Other vaccine allergy desensitization injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Plaque psoriasis</keyword>
	<keyword>Antipsoriatic</keyword>
</DOC>